Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 35, Issue -, Pages 1325-1328Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST0351325
Keywords
arabinogalactan; cell wall; drug target; lipoarabinomannan; Mycobocterium tuberculosis
Categories
Funding
- Medical Research Council [G0300056] Funding Source: researchfish
- MRC [G0300056] Funding Source: UKRI
- Medical Research Council [G0300056] Funding Source: Medline
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
in spite of effective antibiotics to treat TB (tuberculosis) since the early 1960s, we enter the new millennium with TB, currently the leading cause of death from a single infectious agent, killing more than three million people worldwide each year. Thus an understanding of drug-resistance mechanisms, the immunobiology of cell wall components to elucidate host-pathogen interactions and the discovery of new drug targets are now required for the treatment of TB. Above the plasma membrane is a classical chemotype IV PG (peptidoglycan) to which is attached the macromolecular structure, mycolyl-arabinogalactan, via a unique diglycosylphosphoryl bridge. This review will discuss the assembly of the mAGP (mycolyl-arabinogalactan-peptidoglycan), its associated glycolipids and the site of action of EMB (ethambutol), bringing forward a new era in TB research and focus on new drugs to combat multidrug resistant TB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available